Role of MicroRNAs in Cognitive Decline Related to COVID‑19 (Review)

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2024 Mar 13

PMID 38476899

Authors

Anastasia Bougea

Vasiliki Epameinondas Georgakopoulou

Ioannis G Lempesis

George Fotakopoulos

Petros Papalexis

Pagona Sklapani

Nikolaos Trakas

Demetrios A Spandidos

Efthalia Angelopoulou

Affiliations

Soon will be listed here.

Abstract

The likelihood and severity of cognitive decline related to coronavirus disease 2019 (COVID-19) have been shown to be reflected by the severity of the infection and concomitant alterations in specific biomarkers. The present review discusses the role of microRNAs (miRNAs/miRs) as biomarkers in COVID-19 and the potential molecular mechanisms of cognitive dysfunction related to COVID-19. A systematic search of published articles was carried out from January 31, 2000 to December 31, 2022 using the PubMed, ProQuest, Science Direct and Google Scholar databases, combining the following terms: 'COVID-19' OR 'SARS-CoV-2' OR 'post-COVID-19 effects' OR 'cognitive decline' OR 'neurodegeneration' OR 'microRNAs'. The quality of the evidence was evaluated as high, moderate, low, or very low based on the GRADE rating. A total of 36 studies were identified which demonstrated reduced blood levels of miR-146a, miR-155, Let-7b, miR 31 and miR-21 in patients with COVID-19 in comparison with a healthy group. The overexpression of the Let-7b may result in the downregulation of BCL-2 during COVID-9 by adjusting the immune responses between chronic inflammatory disease, type 2 diabetes, COVID-19 and cognitive impairment. The reduced expression of miR-31 is associated with cognitive dysfunction and increased microcoagulability in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). miR-155 mediates synaptic dysfunction and the dysregulation of neurotransmitters due to acute inflammation, leading to brain atrophy and a subcortical cognitive profile. The downregulation of miR-21 in patients with COVID-19 aggravates systemic inflammation, mediating an uncontrollable immune response and the failure of T-cell function, provoking cognitive impairment in patients with SARS-CoV-2. On the whole, the present review indicates that dysregulated levels of miR-146a, miR-155, Let-7b, miR-31, and miR-21 in the blood of individuals with COVID-19 are associated with cognitive decline, the chronic activation of immune mechanisms, the cytokine storm, and the vicious cycle of damage and systemic inflammation.

References

Kozomara A, Birgaoanu M, Griffiths-Jones S . miRBase: from microRNA sequences to function. Nucleic Acids Res. 2018; 47(D1):D155-D162. PMC: 6323917. DOI: 10.1093/nar/gky1141. View

Ma X, Becker Buscaglia L, Barker J, Li Y . MicroRNAs in NF-kappaB signaling. J Mol Cell Biol. 2011; 3(3):159-66. PMC: 3104013. DOI: 10.1093/jmcb/mjr007. View

Huang Y, Liu Y, Huang J, Gao L, Wu Z, Wang L . Let‑7b‑5p promotes cell apoptosis in Parkinson's disease by targeting HMGA2. Mol Med Rep. 2021; 24(5). PMC: 8485123. DOI: 10.3892/mmr.2021.12461. View

Bougea A, Koros C, Stefanis L . Salivary alpha-synuclein as a biomarker for Parkinson's disease: a systematic review. J Neural Transm (Vienna). 2019; 126(11):1373-1382. DOI: 10.1007/s00702-019-02062-4. View

Tili E, Mezache L, Michaille J, Amann V, Williams J, Vandiver P . microRNA 155 up regulation in the CNS is strongly correlated to Down's syndrome dementia. Ann Diagn Pathol. 2018; 34:103-109. DOI: 10.1016/j.anndiagpath.2018.03.006. View

Kumar S, Reddy P . Are circulating microRNAs peripheral biomarkers for Alzheimer's disease?. Biochim Biophys Acta. 2016; 1862(9):1617-27. PMC: 5343750. DOI: 10.1016/j.bbadis.2016.06.001. View

Eusebi P, Giannandrea D, Biscetti L, Abraha I, Chiasserini D, Orso M . Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson's disease: A systematic review and meta-analysis. Mov Disord. 2017; 32(10):1389-1400. DOI: 10.1002/mds.27110. View

Candido S, Lupo G, Pennisi M, Basile M, Anfuso C, Petralia M . The analysis of miRNA expression profiling datasets reveals inverse microRNA patterns in glioblastoma and Alzheimer's disease. Oncol Rep. 2019; 42(3):911-922. PMC: 6682788. DOI: 10.3892/or.2019.7215. View

Henry R, Doran S, Barrett J, Meadows V, Sabirzhanov B, Stoica B . Inhibition of miR-155 Limits Neuroinflammation and Improves Functional Recovery After Experimental Traumatic Brain Injury in Mice. Neurotherapeutics. 2018; 16(1):216-230. PMC: 6361054. DOI: 10.1007/s13311-018-0665-9. View

10.

Georgakopoulou V, Gkoufa A, Damaskos C, Papalexis P, Pierrakou A, Makrodimitri S . COVID-19-associated acute appendicitis in adults. A report of five cases and a review of the literature. Exp Ther Med. 2022; 24(1):482. PMC: 9214594. DOI: 10.3892/etm.2022.11409. View

11.

Leidinger P, Backes C, Deutscher S, Schmitt K, Mueller S, Frese K . A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol. 2013; 14(7):R78. PMC: 4053778. DOI: 10.1186/gb-2013-14-7-r78. View

12.

Islam M, Chowdhury U, Nain Z, Uddin S, Ahmed M, Moni M . Identifying molecular insight of synergistic complexities for SARS-CoV-2 infection with pre-existing type 2 diabetes. Comput Biol Med. 2021; 136:104668. PMC: 8299293. DOI: 10.1016/j.compbiomed.2021.104668. View

13.

Bautista-Becerril B, Perez-Dimas G, Sommerhalder-Nava P, Hanono A, Martinez-Cisneros J, Zarate-Maldonado B . miRNAs, from Evolutionary Junk to Possible Prognostic Markers and Therapeutic Targets in COVID-19. Viruses. 2022; 14(1). PMC: 8781105. DOI: 10.3390/v14010041. View

14.

. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View

15.

Khatoon F, Prasad K, Kumar V . COVID-19 associated nervous system manifestations. Sleep Med. 2021; 91:231-236. PMC: 8267101. DOI: 10.1016/j.sleep.2021.07.005. View

16.

Wang Y, Chang Q . MicroRNA miR-212 regulates PDCD4 to attenuate Aβ-induced neurotoxicity via PI3K/AKT signaling pathway in Alzheimer's disease. Biotechnol Lett. 2020; 42(9):1789-1797. DOI: 10.1007/s10529-020-02915-z. View

17.

Conti I, Varano G, Simioni C, Laface I, Milani D, Rimondi E . miRNAs as Influencers of Cell-Cell Communication in Tumor Microenvironment. Cells. 2020; 9(1). PMC: 7016744. DOI: 10.3390/cells9010220. View

18.

Barros-Viegas A, Carmona V, Ferreiro E, Guedes J, Cardoso A, Cunha P . miRNA-31 Improves Cognition and Abolishes Amyloid-β Pathology by Targeting APP and BACE1 in an Animal Model of Alzheimer's Disease. Mol Ther Nucleic Acids. 2020; 19:1219-1236. PMC: 7031139. DOI: 10.1016/j.omtn.2020.01.010. View

19.

Kuo M, Liu S, Hsu Y, Wu R . The role of noncoding RNAs in Parkinson's disease: biomarkers and associations with pathogenic pathways. J Biomed Sci. 2021; 28(1):78. PMC: 8603508. DOI: 10.1186/s12929-021-00775-x. View

20.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View